Efficacy and Safety of biosimilars of Filgrastim in patients who underwent autologous stem cell transplantation

Trial Profile

Efficacy and Safety of biosimilars of Filgrastim in patients who underwent autologous stem cell transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Lymphoma; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top